Han Kun and its Hong Kong associated law firm advise on Huakang Biomedical Holdings' Hong Kong IPO
December, 2018 - Hong Kong, Mainland China
Han Kun Law Offices and its Hong Kong associated law firm advised RHB Capital Hong Kong Limited, the sole sponsor, on the listing of Huakang Biomedical Holdings Company Limited (Stock Code: 8622) on the Growth Enterprise Market board of the Stock Exchange of Hong Kong.
Huakang is a medical device group specialized in the research and development, manufacture and sale of a wide range of in-vitro diagnostic reagents in China.
